← Ramkhamhaeng Hospital overview

Ramkhamhaeng Hospital vs U.S. Physical Therapy: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Ramkhamhaeng Hospital Public Company Limited (RAM.BK)

Q3 2026
▲2▼1

RAM's profit jumps on hospital takeovers, but competition and weak demand weigh

  • RAM buys three hospitals, adds Khon Kaen Ram as subsidiary RAM spent 593 million baht to buy stakes in three hospitals, making Khon Kaen Ram a subsidiary. This means RAM can now include Khon Kaen Ram's revenue and profit in its own financial statements, boosting reported growth and expanding its hospital network.

    This is a major acquisition that directly boosts RAM's financials and growth story.

  • RAM's Q2 profit rises 29% on consolidating THG and CMH RAM reported Q2 2026 net profit of 345 million baht, up 29% from a year earlier, because it now includes the results of Thonburi Healthcare Group (THG) and Chiang Mai Ram (CMH) in its own accounts. Revenue more than doubled, though costs rose faster, so profit margin slipped.

    This is the actual earnings result that shows the impact of RAM's consolidation strategy.

  • Premium clinics in public hospitals intensify competition CGSI warns that new premium clinics in public hospitals are increasing competition for private hospitals like RAM, especially mid-tier ones. This could lead to price wars, higher marketing costs, and poaching of doctors. CGSI cut RAM's earnings estimates and target price but kept a hold rating.

    This is a key competitive threat that pressures RAM's pricing and profitability.

  • Weak domestic demand and Middle East conflict hurt, but recovery expected Analysts say hospital profits bottomed in Q2 2026 due to weak domestic spending and the US-Iran conflict reducing international patients. RAM is expected to recover in H2, with Q3 net profit likely up year-on-year, helped by a low base and the THG merger. However, competition and economic slowdown remain risks.

    This captures the overall sector trend and RAM's expected recovery, balancing negative and positive forces.

August 2026
▲2▼1

RAM's profit jumps on hospital takeovers, but competition and weak demand weigh

  • RAM buys three hospitals, adds Khon Kaen Ram as subsidiary RAM spent 593 million baht to buy stakes in three hospitals, making Khon Kaen Ram a subsidiary. This means RAM can now include Khon Kaen Ram's revenue and profit in its own financial statements, boosting reported growth and expanding its hospital network.

    This is a major acquisition that directly boosts RAM's financials and growth story.

  • RAM's Q2 profit rises 29% on consolidating THG and CMH RAM reported Q2 2026 net profit of 345 million baht, up 29% from a year earlier, because it now includes the results of Thonburi Healthcare Group (THG) and Chiang Mai Ram (CMH) in its own accounts. Revenue more than doubled, though costs rose faster, so profit margin slipped.

    This is the actual earnings result that shows the impact of RAM's consolidation strategy.

  • Premium clinics in public hospitals intensify competition CGSI warns that new premium clinics in public hospitals are increasing competition for private hospitals like RAM, especially mid-tier ones. This could lead to price wars, higher marketing costs, and poaching of doctors. CGSI cut RAM's earnings estimates and target price but kept a hold rating.

    This is a key competitive threat that pressures RAM's pricing and profitability.

  • Weak domestic demand and Middle East conflict hurt, but recovery expected Analysts say hospital profits bottomed in Q2 2026 due to weak domestic spending and the US-Iran conflict reducing international patients. RAM is expected to recover in H2, with Q3 net profit likely up year-on-year, helped by a low base and the THG merger. However, competition and economic slowdown remain risks.

    This captures the overall sector trend and RAM's expected recovery, balancing negative and positive forces.

Latest
▲2▼1

RAM's profit jumps on hospital takeovers, but competition and weak demand weigh

  • RAM buys three hospitals, adds Khon Kaen Ram as subsidiary RAM spent 593 million baht to buy stakes in three hospitals, making Khon Kaen Ram a subsidiary. This means RAM can now include Khon Kaen Ram's revenue and profit in its own financial statements, boosting reported growth and expanding its hospital network.

    This is a major acquisition that directly boosts RAM's financials and growth story.

  • RAM's Q2 profit rises 29% on consolidating THG and CMH RAM reported Q2 2026 net profit of 345 million baht, up 29% from a year earlier, because it now includes the results of Thonburi Healthcare Group (THG) and Chiang Mai Ram (CMH) in its own accounts. Revenue more than doubled, though costs rose faster, so profit margin slipped.

    This is the actual earnings result that shows the impact of RAM's consolidation strategy.

  • Premium clinics in public hospitals intensify competition CGSI warns that new premium clinics in public hospitals are increasing competition for private hospitals like RAM, especially mid-tier ones. This could lead to price wars, higher marketing costs, and poaching of doctors. CGSI cut RAM's earnings estimates and target price but kept a hold rating.

    This is a key competitive threat that pressures RAM's pricing and profitability.

  • Weak domestic demand and Middle East conflict hurt, but recovery expected Analysts say hospital profits bottomed in Q2 2026 due to weak domestic spending and the US-Iran conflict reducing international patients. RAM is expected to recover in H2, with Q3 net profit likely up year-on-year, helped by a low base and the THG merger. However, competition and economic slowdown remain risks.

    This captures the overall sector trend and RAM's expected recovery, balancing negative and positive forces.

U.S. Physical Therapy, Inc. (USPH)

Q3 2026
▲2

USPH grows visits and buys clinics, but costs squeeze profit

  • Record visits and rates, but profit squeezed by costs USPH's Q2 revenue rose 8.5% to $214.1 million, with record per-visit rates and all-time-high visits per clinic. But net income fell to $9.9 million from $12.4 million as employee health costs and new hiring ate into margins. Growth is real, yet profit is shrinking — that tug-of-war is what moves the stock.

    It is the core new earnings result and explains the mixed pressure on USPH's price.

  • Hospital alliances open a new growth path Management is pushing partnerships with hospital systems like NYU Langone, now 60 New York locations, which bring steadier patient volumes and flat, predictable per-visit payments. The injury-prevention unit has grown to about $120 million in revenue with roughly double the margins of the core therapy business.

    It is the newest strategic driver management is betting on for future growth.

  • New permanent CFO ends leadership uncertainty USPH named Nchacha Etta, a former Omnicell and Johnson & Johnson Vision finance chief, as CFO effective September 1, ending the interim period that began in April. A settled finance leadership is a modest positive, though it does not change the underlying business.

    It is a genuinely new company event that removes an overhang on the stock.

  • Acquisitions keep growing, but debt and cash tighten USPH closed three deals this year for $37.6 million, adding about $27 million of annual revenue, and reaffirmed full-year EBITDA guidance of $102–106 million. But cash fell to $24.9 million while credit borrowings rose to $221 million, so the buying spree is being funded with debt.

    It shows the growth engine and its financing cost, a real counterweight for investors.

August 2026
▲2

USPH grows visits and buys clinics, but costs squeeze profit

  • Record visits and rates, but profit squeezed by costs USPH's Q2 revenue rose 8.5% to $214.1 million, with record per-visit rates and all-time-high visits per clinic. But net income fell to $9.9 million from $12.4 million as employee health costs and new hiring ate into margins. Growth is real, yet profit is shrinking — that tug-of-war is what moves the stock.

    It is the core new earnings result and explains the mixed pressure on USPH's price.

  • Hospital alliances open a new growth path Management is pushing partnerships with hospital systems like NYU Langone, now 60 New York locations, which bring steadier patient volumes and flat, predictable per-visit payments. The injury-prevention unit has grown to about $120 million in revenue with roughly double the margins of the core therapy business.

    It is the newest strategic driver management is betting on for future growth.

  • New permanent CFO ends leadership uncertainty USPH named Nchacha Etta, a former Omnicell and Johnson & Johnson Vision finance chief, as CFO effective September 1, ending the interim period that began in April. A settled finance leadership is a modest positive, though it does not change the underlying business.

    It is a genuinely new company event that removes an overhang on the stock.

  • Acquisitions keep growing, but debt and cash tighten USPH closed three deals this year for $37.6 million, adding about $27 million of annual revenue, and reaffirmed full-year EBITDA guidance of $102–106 million. But cash fell to $24.9 million while credit borrowings rose to $221 million, so the buying spree is being funded with debt.

    It shows the growth engine and its financing cost, a real counterweight for investors.

Latest
▲2

USPH grows visits and buys clinics, but costs squeeze profit

  • Record visits and rates, but profit squeezed by costs USPH's Q2 revenue rose 8.5% to $214.1 million, with record per-visit rates and all-time-high visits per clinic. But net income fell to $9.9 million from $12.4 million as employee health costs and new hiring ate into margins. Growth is real, yet profit is shrinking — that tug-of-war is what moves the stock.

    It is the core new earnings result and explains the mixed pressure on USPH's price.

  • Hospital alliances open a new growth path Management is pushing partnerships with hospital systems like NYU Langone, now 60 New York locations, which bring steadier patient volumes and flat, predictable per-visit payments. The injury-prevention unit has grown to about $120 million in revenue with roughly double the margins of the core therapy business.

    It is the newest strategic driver management is betting on for future growth.

  • New permanent CFO ends leadership uncertainty USPH named Nchacha Etta, a former Omnicell and Johnson & Johnson Vision finance chief, as CFO effective September 1, ending the interim period that began in April. A settled finance leadership is a modest positive, though it does not change the underlying business.

    It is a genuinely new company event that removes an overhang on the stock.

  • Acquisitions keep growing, but debt and cash tighten USPH closed three deals this year for $37.6 million, adding about $27 million of annual revenue, and reaffirmed full-year EBITDA guidance of $102–106 million. But cash fell to $24.9 million while credit borrowings rose to $221 million, so the buying spree is being funded with debt.

    It shows the growth engine and its financing cost, a real counterweight for investors.